A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Solid Tumors

Investigator: Pamela Munster, MD
Sponsor: OncoMed Pharmaceuticals, Inc.

Location(s): United States


This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.